We’re Standing Tall against the impact of CLI

On a mission to change the stats—and the status—of CLI amputations

Micro Medical Solutions was formed to do exactly what our name implies—provide solutions to some of the most pressing unmet needs in microvascular intervention.

Our purpose is to give physicians the minimally invasive tools and technology they need to fight the impact of CLI, to significantly reduce the rate of amputations, to improve clinical outcomes and patient quality of life, and to minimize the financial and human costs associated with the treatment of PAD and CLI.


The goal of better BTK intervention

Micro Medical Solutions has set ambitious goals:

  • We are committed to reduce the number of preventable amputations, thereby reducing the significant morbidity, mortality, and burden of CLI amputations.
  • We’re not just asking important questions in BTK intervention—we’re working on the solutions right now.

Could CLI cases have a different outcome with improved treatment options?

Are we doing everything we can to prevent the cascade that leads to amputations?

How can we look at the problem differently and develop better treatment options?

What if BTK intervention could actually start BTK?

We are dedicating more focus on finding specific solutions for better access to long lesions and CTOs in the peripheral arteries. Developing an innovative pedal access platform with an industry-leading small guide is just one way we are working on the solutions.

See more about our progress here.


Visionary leadership and experience

The Micro Medical Solutions leadership team represents a combined 100 years of experience in interventional technology and procedures.

Experience matters, but the ability to develop future BTK solutions matters even more

Founder and CEO, Greg Sullivan leads the MMS management team. Mr. Sullivan has extensive experience in the Medical Device Industry with over 25 years in the minimally invasive neurology and cardiology market.

Jihad Mustapha, MD, Chief Medical Officer has been instrumental in guiding clinical and regulatory pathways for MMS. Dr. Mustapha is a global thought leader for the treatment of patients with Critical Limb Ischemia as well as amputation prevention.

Greg Mathison, Director, Regulatory and Clinical Affairs, has more than 35 years of experience in the healthcare industry and has supported the regulatory pathway for 510k approval for more than 200 product submissions to the FDA. He also has been instrumental in the submission of IDE and PMA applications to the FDA, as well as technical dossiers to foreign governments for CE Mark approval.

Tim Robinson, Director, Research and Development, has over 26 years of experience in developing minimally invasive products for the medical device industry. He has an extensive background in developing devices for the cardiovascular and neurovascular markets, with a primary focus on stent delivery platforms, balloon-based therapeutic catheters, and steerable sheaths and guiding systems.

Back To Top